




Essai Clinique

Généré le 29 mars 2024 à partir de

Titre	Suivi à long terme des participants exposés au GSK3377794 (NY-ESO-1C259T), un traitement par des lymphocytes T génétiquement créés et porteurs d'un récepteur des lymphocytes T ciblant le NY ESO-1
Protocole ID	GSK 208750
ClinicalTrials.gov ID	NCT03391778
Type(s) de cancer	Autre
Phase	Autres
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL  PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	
Investigateur principal	Dr Jonathan Noujaim
Coordonnateur	Olivier Cormier 514-252-3400 poste 5966
Statut	Actif en recrutement
But étude	This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who have, during the interventional study, received GSK3377794 generated by a process that utilizes lentiviral vectors. Subjects enrolled in the interventional studies who complete the interventional study or who withdraw from the interventional study will enter this LTFU study and will be followed for up to 15 years from the infusion of genetically modified T lymphocytes. Subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
Critères d'éligibilité	<ul style="list-style-type: none">• Subjects who have received at least one dose of GSK3377794 in the interventional study.• Subjects who have either completed the interventional study or have withdrawn from it.• Male or Female subjects.• Capable of giving signed informed consent prior to the study participation.
Critères d'exclusion	<ul style="list-style-type: none">• None